Targeted CEA CAR-T

Phase 1Cell therapy

CChongqing Precision Biotech Co., Ltd

Targeted CEA CAR-T is one of 55 biologic programs targeting Lung Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerRecruiting

Lung CarcinomaRecruiting

Lung CancerPhase 1

Recruiting

Lung CarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

206 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Tagrisso

AstraZeneca

Phase 3

19 2

Beyfortus

BeiGene

Phase 3

10 3

Abraxane

Bristol-Myers Squibb

Phase 3

7 4

Alecensa

Roche

Phase 3

3 5

Ilaris

Novartis

Phase 3

2 6

Verzenio

Eli Lilly

Phase 3

2 7

DATROWAY

Daiichi Sankyo

Phase 3

2 8

Lynparza

AstraZeneca

Phase 3

2 9

Zepzelca

Jazz Pharmaceuticals

Phase 3

2 10

Tarlatamab-Dznl

Amgen

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Lung Cancer

NCT06768151

Q1 2028

Phase 1Recruiting

Lung Carcinoma

NCT06903117

Q2 2028

Phase 1Recruiting

Lung Cancer

NCT06992583

Phase 1Recruiting

Lung Cancer

NCT06945523

Clinical

Trials by Indication[1]

Lung Cancer3 trials

A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer

Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT06768151·48 enrolled

Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer

Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT06992583·60 enrolled

Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer

Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT06945523·60 enrolled

Lung Carcinoma1 trial

Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma

Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT06903117·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Targeted CEA CAR-T. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Targeted CEA CAR-T compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Targeted CEA CAR-T. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chongqing Precision Biotech Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: CChongqing Precision Biotech Co., Ltd

Targeted CEA CAR-T

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Q2 2028

Trials by Indication[1]

Lung Cancer3 trials

Lung Carcinoma1 trial

References

Drug Info

Quick Facts

Related News